Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Longitudinal safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in children aged 4-11 years with juvenile-onset autoimmune inflammatory rheumatic diseases: A prospective multicenter study.
Eviatar T, Ziv A, Oved A, Miller-Barmak A, Pappo A, Livny R, Amarilyo G, Aviel YB, Naor R, Pel S, Furer V, Elkayam O, Uziel Y, Heshin-Bekenstein M. Eviatar T, et al. Among authors: miller barmak a. Vaccine. 2024 Dec 2;42(26):126426. doi: 10.1016/j.vaccine.2024.126426. Epub 2024 Oct 17. Vaccine. 2024. PMID: 39423454
E148Q variant: a familial Mediterranean fever-causing mutation or a sequence variant?
Orouk Awaad E, Khoury L, van Straalen JW, Miller-Barmak A, Gazitt T, Haddad-Haloun J, Brik R, Hamad Saied M. Orouk Awaad E, et al. Among authors: miller barmak a. Eur J Pediatr. 2024 Oct;183(10):4499-4506. doi: 10.1007/s00431-024-05690-5. Epub 2024 Aug 15. Eur J Pediatr. 2024. PMID: 39143349 Free PMC article.
An "On Demand" canakinumab regimen for treating children with Colchicine-Resistant familial Mediterranean fever - A multicentre study.
Shehadeh K, Levinsky Y, Kagan S, Zuabi T, Tal R, Aviran NH, Butbul Aviel Y, Tirosh I, Spielman S, Miller-Barmak A, Semo Oz R, Harel L, Chodick G, Amarilyo G. Shehadeh K, et al. Among authors: miller barmak a. Int Immunopharmacol. 2024 May 10;132:111967. doi: 10.1016/j.intimp.2024.111967. Epub 2024 Apr 3. Int Immunopharmacol. 2024. PMID: 38569431
Safety and Immunogenicity Following the Second and Third Doses of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents with Juvenile-Onset Autoimmune Inflammatory Rheumatic Diseases: A Prospective Multicentre Study.
Heshin-Bekenstein M, Ziv A, Toplak N, Lazauskas S, Kadishevich D, Ben-Nun Yaari E, Miller-Barmak A, Butbul Aviel Y, Saiag E, Pel S, Elkayam O, Uziel Y, Furer V. Heshin-Bekenstein M, et al. Among authors: miller barmak a. Vaccines (Basel). 2023 Apr 10;11(4):819. doi: 10.3390/vaccines11040819. Vaccines (Basel). 2023. PMID: 37112731 Free PMC article.
Infantile Takayasu: clinical features and long-term outcome.
Miller-Barmak A, Sztajnbok F, Balik Z, Borzutzky A, Fogel LA, Goldzweig O, Ozen S, Butbul Aviel Y. Miller-Barmak A, et al. Rheumatology (Oxford). 2023 Sep 1;62(9):3126-3132. doi: 10.1093/rheumatology/keac691. Rheumatology (Oxford). 2023. PMID: 36495199